TY - GEN
T1 - Atrial defibrillation using transcutaneous radio-frequency pulse delivery
AU - Manoharan, G
AU - Santos, JA
AU - Evans, NE
AU - Anderson, JMCC
AU - Kidawi, BJ
AU - Allen, JD
AU - Adgey, AAJ
N1 - Reference text: [ 1] J. D. Bronzino, The Biomedical Engineering Handbook. CRC Press & IEEE Press, pp. 1275-1291, 1995.
[2] L. D. Hillis, J. E. Ormand, and J. T. Willerson, Manual of Clinical Problems in Cardiology, lst Ed., pp. 13-14. Boston, USA: Little Brown and Company, 1980.
[3] A. Timmis, and A. Nathan, Essentials of Cardiology, 2"d Ed., pp. 228-239. Blackwell Scientific Publications, 1993.
[4] P. Touboul, “Atrial Defibrillator: Is It Needed? Would Society Pay For It?,” PACE, Vol. 18 (Pt. 11), pp. 616-621, 1995.
[5] P. E. K. Donaldson, “Frequency-hopping in r.f. energy-transfer links,” Electronics h Wireless World, pp. 24-26, August 1986.
[6] N. Donaldson and T.A. Perkins, “Analysis of resonant coupled coils in the design of radio frequency transcutaneous links,” Med. Biol. Eng. h Cornput., Vol. 21, pp. 612- 627, September 1983
PY - 2001/11
Y1 - 2001/11
N2 - Atrial fibrillation (AF) is one of the most common sustained cardiac arrhythmias found. Its treatment requires the use of a synchronised electrical shock or drug therapy. This paper describes a new form of electrical defibrillator that employs a two-part, transdermal RF transformer to couple an on-off keyed 7.2 MHz pulse to an implanted, passive receiver; this, in turn, delivers a unipolar DC shock to the heart. Factors influencing the transformer's design are discussed and results from axial and lateral primary/secondary coil displacement trials presented. In animal studies, cardioversion was 100% successful with pulses of 100 V amplitude and 10 ms width. The implant is battery-free, which makes it an attractive and inexpensive alternative for the treatment of AF.
AB - Atrial fibrillation (AF) is one of the most common sustained cardiac arrhythmias found. Its treatment requires the use of a synchronised electrical shock or drug therapy. This paper describes a new form of electrical defibrillator that employs a two-part, transdermal RF transformer to couple an on-off keyed 7.2 MHz pulse to an implanted, passive receiver; this, in turn, delivers a unipolar DC shock to the heart. Factors influencing the transformer's design are discussed and results from axial and lateral primary/secondary coil displacement trials presented. In animal studies, cardioversion was 100% successful with pulses of 100 V amplitude and 10 ms width. The implant is battery-free, which makes it an attractive and inexpensive alternative for the treatment of AF.
U2 - 10.1109/ANZIIS.2001.974096
DO - 10.1109/ANZIIS.2001.974096
M3 - Conference contribution
SP - 313
EP - 316
BT - Unknown Host Publication
PB - IEEE
T2 - The Seventh Australian and New Zealand Intelligent Information Systems Conference, ANZIIS
Y2 - 1 November 2001
ER -